title: [Perioperative therapies in surgical non N2 non-small cell lung cancer].
abstract: Platinum-based perioperative chemotherapy is actually the standard of care in stage II-IIIa non-small cell lung cancer (NSCLC). A benefit may also be seen in stage IB NSCLC with tumors of more than 4cm of diameter. Perioperative chemotherapy improves 5-year survival of 4 to 15%. This benefit is mainly proved by postoperative chemotherapy trials. Nevertheless, preoperative chemotherapy has advantages: a better tolerance, an estimation of tumor chemosensibility, without an increased postoperative morbimortality. However, pTNM and pathological tumor analyses are modified. Indications of postoperative radiotherapy are limited. In early stage NSCLC (stage I-II), radiotherapy worsens survival. Radiotherapy is routinely achieved in NSCLC with parietal tumor invasion and incomplete tumor resection. Indications of immunotherapy and targeted therapies in case of oncogenic addiction remain to be established in resected NSCLC. Several biomarkers are studied to better describe the indications of perioperative chemotherapy: recognize groups of patients with a worse prognosis and distinguish chemosensibility of the tumor.
authors.affiliation: AP-HP, hôpital Tenon, service de pneumologie, 75970 Paris, France; Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France.
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Ruppert
authors.affiliation: AP-HP, hôpital Tenon, service de pneumologie, 75970 Paris, France; Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France.
authors.forename: Armelle
authors.initials: A
authors.lastname: Lavolé
authors.affiliation: AP-HP, hôpital Tenon, service de chirurgie thoracique, 75970 Paris, France.
authors.forename: Jalal
authors.initials: J
authors.lastname: Assouad
authors.affiliation: AP-HP, hôpital Tenon, service de pneumologie, 75970 Paris, France; Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
authors.affiliation: AP-HP, hôpital Tenon, service de pneumologie, 75970 Paris, France; Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France. Electronic address: marie.wislez@aphp.fr.
authors.forename: Marie
authors.initials: M
authors.lastname: Wislez
mesh_terms: D000367:Age Factors; D014408:Biomarkers, Tumor / Q000032:analysis; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D055118:Medication Adherence; D058990:Molecular Targeted Therapy; D020360:Neoadjuvant Therapy; D017671:Platinum Compounds / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor; D017671:Platinum Compounds
keywords: Adjuvant chemotherapy; Cancer bronchique non à petites cellules; Chemotherapy; Chimiothérapie; Chimiothérapie adjuvante; Chimiothérapie néo-adjuvante; Neo-adjuvant chemotherapy; Non small cell lung cancer; Radiotherapy; Radiothérapie